Frequently Asked Questions

AlphaRose Therapeutics, Inc. is a Delaware Public Benefit Corporation headquartered in Austin, Texas, dedicated to developing antisense oligonucleotide (ASO) therapies for children diagnosed with ultra-rare genetic diseases. Founded in 2023, AlphaRose combines a vertically integrated preclinical CRO (RareLabs), proprietary antisense chemistry (abcDNA), and AI-powered drug design tools to bring life-changing treatments from bench to bedside faster and at a fraction of the traditional cost.

Antisense oligonucleotides are short, synthetic strands of nucleic acids designed to bind to a specific target messenger RNA (mRNA) and modulate gene expression. ASOs can silence a harmful gene, correct a splicing error, or restore production of a missing protein. They represent a powerful class of precision medicine because each ASO can be custom-designed to target a specific genetic mutation, making them ideal for treating rare genetic diseases.

AlphaRose operates a vertically integrated platform with three revenue-generating components. First, RareLabs, the company’s internal preclinical CRO, generates near-term revenue by running preclinical programs for rare disease families and foundations at $100,000 to $200,000 per program. Second, the company develops its own proprietary pipeline of ASO therapies (starting with Rosiphersen) for clinical development. Third, AlphaRose’s abcDNA chemistry and AI design tools create licensing and partnership opportunities with larger pharmaceutical companies.

AlphaRose is led by Casey McPherson as Chief Executive Officer and Masako Nakamura as Chief Operating Officer. The company’s Board of Directors includes Casey McPherson, Alan Walts, Belinda Termeer, Lance Hirsch, and John Capezzuti — bringing deep expertise in rare disease therapeutics, pharmaceutical development, and corporate governance.

AlphaRose is an early-stage biopharmaceutical company with a validated preclinical platform. The company has completed multiple preclinical programs through RareLabs, acquired differentiated IP (abcDNA), hired key executive leadership, and is advancing its lead candidate Rosiphersen toward IND-enabling studies. RareLabs is targeting $1.4 million in revenue for 2026, providing near-term cash flow while the proprietary pipeline matures.

AlphaRose and RareLabs maintain active collaborations with a range of leading institutions and companies, including AstraZeneca, Charles River Labs, Curi Bio, Facet Life Sciences, JAX Lab, Ask Bio, Southern Research, Queensland University Australia, Columbus Children’s Hospital, and Fortrea. These partnerships span drug design, preclinical services, and clinical development infrastructure.

The global rare disease therapeutics market is valued at over $200 billion and growing rapidly. Regulatory incentives such as the U.S. Orphan Drug Act provide significant benefits including seven years of market exclusivity, tax credits, and reduced FDA fees. With approximately 7,000 known rare diseases and fewer than 5% having an approved treatment, the unmet need — and the market opportunity — is enormous.

The To Cure a Rose Foundation (TCAR) is a Texas non-profit corporation founded by Casey McPherson to fund research into treatments for his daughter Rose’s HNRNPH2 diagnosis. TCAR originally operated the preclinical laboratory that became RareLabs. In December 2025, TCAR transferred RareLabs’ assets to AlphaRose Therapeutics, enabling the commercial entity to scale the lab’s work while the foundation continues its charitable mission.